Comparative Pharmacology
Head-to-head clinical analysis: SANCTURA XR versus TROPICAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANCTURA XR versus TROPICAMIDE.
SANCTURA XR vs TROPICAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
Antimuscarinic agent that blocks acetylcholine at muscarinic receptors in the ciliary muscle and sphincter muscle of the iris, resulting in mydriasis and cycloplegia.
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated in 5 minutes if needed for maximal effect; for cycloplegic refraction, 1-2 drops of 1% solution repeated in 5 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Clinical Note
moderateTropicamide + Fesoterodine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine."
Clinical Note
moderateTropicamide + Quinidine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine."
Clinical Note
moderateTropicamide + Darifenacin
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Darifenacin."
Clinical Note
moderateTropicamide + Topiramate
Terminal elimination half-life is approximately 2 hours; clinically, mydriasis and cycloplegia persist for 4-8 hours despite rapid plasma clearance.
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Primarily renal excretion of unchanged drug and metabolites; approximately 30% unchanged in urine within 6 hours; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Topiramate."